Patient satisfaction with an injection device for multiple sclerosis treatment
Abstract:Cramer JA, Cuffel BJ, Divan V, Al-Sabbagh A, Glassman M. Patient satisfaction with an injection device for multiple sclerosis treatment.
Acta Neurol Scand 2006: 113: 156–162 © 2006 The Authors Journal compilation © 2006 Blackwell Munksgaard. Objectives –
To develop a measure of treatment satisfaction assessing attributes specific to injected interferon-beta-1a (IFN-β-1a) for multiple sclerosis (MS), and to test pain and instrument sensitivity to change among patients changing injection devices. Materials and methods –
The MS Treatment Concerns Questionnaire (MSTCQ) was developed and tested with pain assessments before and 3 months after patients changed devices from Rebiject to Rebiject II. Results –
The MSTCQ was organized with two domains: Injection System Satisfaction and Side Effects (three subscales: Injection Site Reactions, Global Satisfaction, and Flu-Like Symptoms). Significant improvements (P = 0.002 to P < 0.001) occurred with the new injection device in all MSTCQ subscales (except Flu-Like Symptoms), and all pain measures (P < 0.0001). Clinically meaningful improvement was demonstrated in all scales, except Flu-Like Symptoms, by effect sizes (0.23–0.59). Conclusions –
These statistically significant and clinically meaningful improvements in MSTCQ and pain measures show the value of technologically advanced devices in domains of concern to patients.
Document Type: Research Article
Affiliations: 1: Department of Psychiatry, Yale University, New Haven, CT, USA 2: Outcomes Research, Pfizer Inc., New York, NY, USA 3: Medical Regulatory Services, Pfizer Inc., New York, NY, USA 4: Medical Affairs Department, Serono S.A., Rockland, MA, USA 5: Statistical Consultant, New York, NY, USA
Publication date: March 1, 2006